biostudies-literatureUnknown8(4)Futatsugi KSmall molecule DGAT2 inhibitors have shown promise for the treatment of metabolic diseases in preclinical models. Herein, we report the first toxicological evaluation of imidazopyridine-based DGAT2 inhibitors and show that the arteriopathy associated with imidazopyridine <b>1</b> can be mitigated with small structural modifications, and is thus not mechanism related.MedChemComm771-779https://www.ebi.ac.uk/biostudies/studies/S-EPMC6072535biostudies-literatureSmall structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.PMC6072535Dowling MSHuard KPurkal JFlynn DAGorczyca WPKung DWShoieb AMHepworth DPerez SMOrr STMGoodwin BNiosi MFutatsugi KBarnes RJFernando DPPettersen JCShirai NZhou JLavergne SSchmahai TJGoosen TCLi QHerr MCabral SPardo IDGosset JRAspnes GEfalseSmall structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.Small molecule DGAT2 inhibitors have shown promise for the treatment of metabolic diseases in preclinical models. Herein, we report the first toxicological evaluation of imidazopyridine-based DGAT2 inhibitors and show that the arteriopathy associated with imidazopyridine <b>1</b> can be mitigated with small structural modifications, and is thus not mechanism related.2017-01-01T00:00:00Z2017 Apr2021-02-21T10:19:37Z2019-03-26T23:51:31ZS-EPMC60725353010879610.1039/c6md00564k